RESUMO
The validity of low-frequency ultrasound (LFU) addition to specific therapy of pulmonary tuberculosis (PT) was investigated in 2 groups of PT new cases. The study group (n = 25) received specific therapy and ultrasonic treatment (44 KHz, amplitude 2 microm to the paravertebral region and PT zones). The control group (n = 25) received specific therapy only. The response to treatment was higher in the study group. The findings support validity of low-frequency ultrasound use as an adjuvant in treatment of PT new cases.
Assuntos
Tuberculose Pulmonar/reabilitação , Terapia por Ultrassom/métodos , Adulto , Antituberculosos/uso terapêutico , Terapia Combinada , Quimioterapia Combinada , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeAssuntos
Adjuvantes Imunológicos/uso terapêutico , Dipeptídeos , Peptídeos/uso terapêutico , Extratos do Timo/uso terapêutico , Hormônios do Timo/uso terapêutico , Tuberculose/tratamento farmacológico , Animais , Avaliação Pré-Clínica de Medicamentos , Sistema Imunitário/efeitos dos fármacos , Sistema Imunitário/imunologia , Sistema Imunitário/patologia , Camundongos , Camundongos Endogâmicos CBA , Linfócitos T/efeitos dos fármacos , Linfócitos T/imunologia , Tuberculose/imunologia , Tuberculose/patologiaRESUMO
The effects of thymogen, thymalin and vilosen in combination with antituberculous drugs (isoniazid, streptomycin, rifampicin) were studied on 240 CBA mice with experimental tuberculosis. Thymus preparations supplemented to the complex treatment of experimental tuberculosis significantly increased their lifespan, contributed to a decrease in the index of spleen weight lung density and significantly increased the count of T lymphocytes and their proliferative activity as compared to those on antituberculous drugs alone. Thymogen was found to be the most effective in the complex treatment of experimental tuberculosis, whereas vilosen was the least. Thymogen plus vilosen proved to be the most beneficial combination of drugs.